Important Medicine Safety Information
Important Medicine Safety Information
Recommended Calculations Of Contraception Duration After Completion Of Therapy To Minimise The Risk Of Embryotoxicity And Teratogenicity Associated With The Use Of Genotoxic Anticancer Medicines (Including Potential Metabolites)
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/IMSIApr24P1.jpg)
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/IMSIApr24P2.jpg)
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/IMSIApr24P3.jpg)
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/IMSIApr24P4.jpg)
The risk of acute tubulointerstitial nephritis (TIN) associated with proton pump inhibitors (PPIs)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/DHCP/Final_DHCP_letter_for_Patient-1.jpg)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/DHCP/Final_DHCP_letter_for_Patient-2.jpg)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/DHCP/Final_DHCP_letter_for_Patient-3.jpg)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/DHCP/Final_DHCP_letter_for_Patient-4.jpg)
GOLIMUMAB SIMPONI 50 MG: IMPORTANT CHANGES TO THE INSTRUCTIONS FOR USE (IFU) FOR THE SMARTJECT AUTOINJECTOR/PRE-FILLED PEN
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/Images/DHCP%20P1.jpg)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/Images/DHCP P2.jpg)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/Images/DHCP P3.jpg)
IMBRUVICA (IBRUTINIB) – RISK OF FATAL CARDIAC EVENTS
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/Signed-SAHPRA-DHCPL--MK-&SC_04.05-p1.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/Signed-SAHPRA-DHCPL--MK-&SC_04.05-p2.png)
COVID-19 VACCINES JANSSEN: RISK OF IMMUNE THROBOCYTOPENIA (ITP) AND VENOUS THROMBOEMBOLISM (VTE)
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/COVID19%20Vaccine%20Janssen_DHCPL_final_Oct%202021p1.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/COVID19 Vaccine Janssen_DHCPL_final_Oct 2021p2.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/COVID19 Vaccine Janssen_DHCPL_final_Oct 2021p3v2.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/COVID19 Vaccine Janssen_DHCPL_final_Oct 2021p4.png)
COVID-19 VACCINE JANSSEN: CONTRADICTION IN INDIVIDUALS WITH PREVIOUS CAPILLARY LEAK SYNDROME (CLS) & RISK OF THROMBOSIS IN COMBINATION WITH THROMBOCYTOPENIA
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/COVID19%20Vaccine%20Janssen_DHCPL_combined%20v2_final%20approved_signed_21Jul21%20p1.png)
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/COVID19%20Vaccine%20Janssen_DHCPL_combined%20v2_final%20approved_signed_21Jul21%20p2.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/COVID19 Vaccine Janssen_DHCPL_combined v2_final approved_signed_21Jul21 p3.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/COVID19 Vaccine Janssen_DHCPL_combined v2_final approved_signed_21Jul21 p4.png)
COVID-19 VACCINE JANSSEN: RISK OF THROMBOSIS IN COMBINATION WITH THROMBOCYTOPENIA
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/Important%20Medicines%20Safety%20Information%20-%20COVID-19%20Vaccine%20Janssen_P1.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/Important Medicines Safety Information - COVID-19 Vaccine Janssen_P2.png)
Warning about cerebro-vascular events, cerebro-vascular accident, cerebral infraction, ischaemic stroke and transcient ischaemic attack associated with the use of tyrosine kinase inhibitor containing medicines
![](https://static.janssen-emea.com/sites/default/files/South%20Africa/Janssen.com/News/1a.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/1b.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/1c.png)
![](https://static.janssen-emea.com/sites/default/files/South Africa/Janssen.com/News/1d.png)